FL30: an epidermal growth factor kinase inhibitor overcoming T790M and C797S mutations through unique conformational...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Tyrosine kinase inhibitors (TKIs) targeting Epidermal Growth Factor Receptor (EGFR) are crucial for non-small cell lung cancer (NSCLC) treatment.
• Fourth-generation TKIs and orthoallosteric inhibitors represent advancements in targeting resistant EGFR mutations like T790M and C797S.

Purpose of the Study:

• To discover and characterize FL30, a novel small molecule inhibitor targeting mutated EGFR.
• To evaluate FL30's efficacy and mechanism of action in preclinical NSCLC models.

Main Methods:

• In vitro biochemical assays to determine potency (IC50) against EGFR mutations.
• In vivo studies using NSCLC models to assess anti-cancer effects.
• Kinetic studies, molecular modeling, and PIR-SEIRA microscopy to elucidate the binding mechanism.

Main Results:

• FL30 demonstrated nanomolar potency against EGFR-L858R/T790M, including the C797S mutation, with efficacy comparable to Osimertinib.
• FL30 selectively inhibited cancer growth and EGFR phosphorylation in NSCLC cells harboring specific EGFR mutations.
• FL30 binds to the orthosteric site and induces an inactive-like conformation in mutant EGFR.

Conclusions:

• FL30 is a potent inhibitor of clinically relevant EGFR mutations in NSCLC.
• The discovery of FL30 validates a therapeutic strategy combining orthosteric binding with allosteric modulation.
• FL30 holds potential for further development as a targeted therapy for NSCLC.